Ishita Drugs and Industries Limited (524400) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Ishita Drugs and Industries Limited ₹44.26, price ₹76.20, upside -41.9%, quality 64 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Ishita Drugs and Industries Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ₹27.25 – ₹96.35 · fair‑value band ₹33.19 – ₹55.32 · the ₹76.20 price screens above the ₹44.26 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow Ishita Drugs and Industries in your weekly email
Every Wednesday you see whether Ishita Drugs and Industries is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Ishita Drugs & Industries Limited manufactures and sells active pharma ingredients and drug intermediates in India.
Show more
Ishita Drugs & Industries Limited manufactures and sells active pharma ingredients and drug intermediates in India. It offers active pharma ingredients, such as sulfa drugs/sulfonamides, vitamins, fluoro quinolones, antibiotics, anthelmintics, iodides and citrates, food additives/excipients, and others; fine chemicals; and drug intermediaries, as well as finished dosage forms. The company also provides contract manufacturing services for various drug intermediates, fine chemicals, or specialty chemicals. It serves regulatory authorities and pharmaceutical companies. The company exports its products to approximately 25 countries. Ishita Drugs & Industries Limited was incorporated in 1992 and is based in Ahmedabad, India.
Stock analysis
Ishita Drugs and Industries Limited (524400) currently trades at ₹76.20, while our model-based Fair Value estimate is ₹44.26, 41.9% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ₹67.46 per share, and 3 of the 22 models we run sit above the ₹76.20 price.
Bear case: the Earnings-Based group reads lowest at ₹17.96, and 19 of the 22 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹33.19 (bear) to ₹55.32 (bull), the price of ₹76.20 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 64/100 (solid quality), in the Health Care sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Ishita Drugs and Industries Limited reported revenue of ₹147M in FY2026 versus ₹141M in FY2022, a compound +1.0%/yr. Reported net income was ₹7.8M in FY2026, compounding −0.8%/yr from FY2022.
Key figures
Market cap ₹64.3M (≈ $668K) · P/E ratio 13.3 · P/S ratio 0.71 · EPS (TTM) ₹1.81 · Net margin 5.3% · Return on equity 7.8% · Return on assets (EBIT) 6.4% · Operating margin 4.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 9% below its 52-week high and 13% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Health Care peers we cover trades at −40% fair-value upside, at −42%, 524400 screens richer than that median.
Fair Value models
Bear ₹33.19Fair Value ₹44.26Bull ₹55.32
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹0.9203 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−2.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.0%
Start year 2021 (pandemic). Over 10 years: +8.4% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.7%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−1.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−1.0%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−1.0% vs 17.2%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → 5%
Start year 2021 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−3.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about −7.7% a year for the price.
Compare Ishita Drugs and Industries Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 51 stocks
Beats the industry median on 9/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score64 · Top 25%
Fair Value upside−41.9% · Below median
Profitability
Return on equity (TTM)7.8% · Above median
Return on assets3.8% · Above median
Net margin (TTM)4.0% · Above median
Operating margin (TTM)4.2% · Below median
Growth and dividend
Revenue growth6.2% · Below median
Dividend yield (TTM)0.0% · Bottom 25%
Balance sheet
Debt / equity0.00× · Below median
Valuation Multiplesvs Pharmaceuticals median · lower = cheaper
P/E (TTM)13.3× · Cheaper than median
P/B0.56× · Cheapest 25%
P/S (TTM)0.48× · Cheaper than median
P/FCF3.1× · Cheaper than median
EV/EBITDA8.4× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 33
FUTURE (revenue growth)31· sector 55
PAST (return on equity)31· sector 10
HEALTH (low debt)100· sector 98
DIVIDEND (yield)0· sector 26
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Ishita Drugs and Industries Limited Fair Value". https://www.fairvalue-calculator.com/stock/524400
Frequently asked questions
Is Ishita Drugs and Industries Limited (524400) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ₹44.26 versus a price of ₹76.20, about −42% upside (overvalued).
What is the fair value of 524400?
Our model-based fair value for Ishita Drugs and Industries Limited is ₹44.26 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹76.20.
What is the quality score of 524400?
Ishita Drugs and Industries Limited has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ishita Drugs and Industries Limited (524400)?
Our model-based price target is the fair value of ₹44.26 (as of Sep 24, 2026) from 22 valuation models. Cautious scenario ₹33.19, optimistic scenario ₹55.32. It is a calculation from audited fundamentals, not an analyst target.
What is the Ishita Drugs and Industries Limited stock forecast for 2026?
Our models put fair value at ₹44.26, about −42% upside versus a price of ₹76.20 (overvalued). Cautious scenario ₹33.19, optimistic scenario ₹55.32. The calculation is refreshed regularly with new filings.
What is the revenue of Ishita Drugs and Industries Limited (524400)?
Ishita Drugs and Industries Limited reported trailing-twelve-month revenue of about ₹135M (latest available figure, as of Sep 24, 2026).
What growth is priced into Ishita Drugs and Industries Limited (524400)?
For today's price to be fair in a discounted-cash-flow model, Ishita Drugs and Industries Limited would have to grow free cash flow by -3.9 % per year for five years (discount rate 12.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +1.0 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 524400 use?
Our models discount Ishita Drugs and Industries Limited at 12.8 %: a base by market capitalisation (nano), damped by beta 1.13, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Ishita Drugs and Industries Limited that is -3.9 % per year a year over ten years, using the same discount rate (12.8 %) and the same formula as our fair value.
How much growth has Ishita Drugs and Industries Limited (524400) delivered so far?
Over the past 5 years revenue at Ishita Drugs and Industries Limited grew +1.0 % a year. The price currently implies -3.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Ishita Drugs and Industries Limited (524400) growing?
The median revenue growth in the sector is +8.1 % a year. That is the yardstick for the growth priced into Ishita Drugs and Industries Limited (-3.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Ishita Drugs and Industries Limited (524400)?
The free-cash-flow yield on the price is 9.08 %: that much free cash flow Ishita Drugs and Industries Limited produces per unit of market value. When it exceeds the discount rate of our models (12.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Ishita Drugs and Industries Limited (524400)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ishita Drugs and Industries Limited it is ₹44.26 per share (as of Sep 24, 2026), against a price of ₹76.20. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is Ishita Drugs and Industries Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 524400 trades above its calculated fair value: price ₹76.20, fair value ₹44.26, a gap of about −42% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 524400?
No. The price is what the market pays today (₹76.20); the fair value is what the company's own numbers justify (₹44.26). For Ishita Drugs and Industries Limited the two are ₹31.94 per share apart. That gap is exactly why we show both numbers side by side.
How much is Ishita Drugs and Industries Limited worth?
The market values Ishita Drugs and Industries Limited at about ₹64.3M (market capitalisation, as of Sep 24, 2026). Per share that is ₹76.20; our models calculate a fair value of ₹44.26 per share.
What do the bullish and bearish scenarios say about 524400?
Our models span a range for Ishita Drugs and Industries Limited: cautious scenario ₹33.19, base ₹44.26, optimistic ₹55.32 per share (as of Sep 24, 2026, price ₹76.20). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 524400?
Ishita Drugs and Industries Limited trades at a price-to-earnings ratio of 13.3 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹44.26 is built from several models across several years. Other multiples: P/B 0.6, P/S 0.5, EV/EBITDA 8.4.
How solid is the balance sheet of Ishita Drugs and Industries Limited (524400)?
Balance-sheet figures for Ishita Drugs and Industries Limited (as of Sep 24, 2026): return on equity 7.8%, debt of 0.00 per unit of equity. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is 524400 from its 52-week high?
Ishita Drugs and Industries Limited trades at ₹76.20, about 9% below its 52-week high of ₹83.57 and 13% above the low of ₹67.60 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹44.26 is for.
Which stocks are comparable to Ishita Drugs and Industries Limited?
From the same area (Health Care) we also value Caregen Co, ST Pharm Co, Oscotec Inc, DongKook Pharmaceutical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ishita Drugs and Industries Limited stock attractive at the current price?
The data as of Sep 24, 2026: price ₹76.20, calculated fair value ₹44.26 (−42%), Quality Score 64/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 524400 calculated?
We run Ishita Drugs and Industries Limited through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹44.26, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Ishita Drugs and Industries Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ishita Drugs and Industries Limited (524400)?
The closing price on Oct 1, 2026 was ₹76.20. Our model-based fair value is ₹44.26, about −42% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ishita Drugs and Industries Limited right now?
The price sits above even our optimistic bull case (₹55.32). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (64/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Ishita Drugs and Industries Limited
How large is the market capitalisation of Ishita Drugs and Industries Limited (524400)?
The market capitalisation of Ishita Drugs and Industries Limited is ₹64.3M (≈ $668K). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ishita Drugs and Industries Limited (524400)?
The price-to-sales ratio of Ishita Drugs and Industries Limited is 0.71 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ishita Drugs and Industries Limited (524400)?
Earnings per share at Ishita Drugs and Industries Limited are ₹1.81 (price ÷ EPS = P/E 13.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Ishita Drugs and Industries Limited (524400)?
The net margin of Ishita Drugs and Industries Limited is 5.3% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ishita Drugs and Industries Limited (524400)?
The return on equity (ROE) of Ishita Drugs and Industries Limited is 7.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ishita Drugs and Industries Limited (524400)?
On an EBIT basis the return on assets of Ishita Drugs and Industries Limited is 6.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ishita Drugs and Industries Limited (524400)?
The operating margin of Ishita Drugs and Industries Limited is 4.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ishita Drugs and Industries Limited (524400)?
Revenue at Ishita Drugs and Industries Limited is growing +6.2% versus a year earlier (3y avg +6.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Ishita Drugs and Industries Limited (524400)?
Earnings per share at Ishita Drugs and Industries Limited are growing +20.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Ishita Drugs and Industries Limited (524400) carry?
The net debt of Ishita Drugs and Industries Limited is ₹33.3M (fiscal year 2025, ≈ 1.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Ishita Drugs and Industries Limited in the live analysis
One click puts Ishita Drugs and Industries Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
